HC Wainwright & Co. Maintains Buy on Regenxbio, Lowers Price Target to $26

REGENXBIO, Inc.

REGENXBIO, Inc.

RGNX

0.00

HC Wainwright & Co. analyst Yi Chen maintains Regenxbio (NASDAQ: RGNX) with a Buy and lowers the price target from $30 to $26.